Oral Contrast Agent Market Growth, Size, Share, Industry Report and Forecast 2021-2027

The global oral contrast agent market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Oral contrast agents are barium- or iodine-based. They are used for bowel opacification. Additionally, the concentration of barium determines if it enhances the diagnosis or causes an artifact and obscures pathology. The major factor driving the demand for oral contrast agent is the new product launches and drug approvals across the globe.

For instance, in December 2021, Bayer announced the approval of two pediatric indications Xarelto (rivaroxaban) from the US Food and Drug Administration (FDA). It is used for the treatment of venous thromboembolism (VTE) and to reduce the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral anticoagulant treatment and thromboprophylaxis in children aged two years and older with congenital heart disease who have undergone the Fontan procedure. Additionally, in December 2021, Ascelia Pharma AB presented a study in which Orviglance was compared against a gadolinium-based contrast agent at RSNA 2021. Orviglance is a novel manganese-based oral contrast agent for magnetic resonance imaging (MRI).

To Request a Sample of our Report on Oral Contrast Agent Market:  https://www.omrglobal.com/request-sample/oral-contrast-agent-market

Some major players in the market include General Electric Co., Bracco Imaging SpA, and Bayer AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Ascelia Pharma AB announced the acceptance of the Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer with the daily oral chemotherapy candidate drug Oncoral from the US Food and Drug Administration (FDA).

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027

Segment Covered- 

  • By Type
  • By Application

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape– General Electric Co., Bracco Imaging SpA, and Bayer AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of Oral Contrast Agent Market is Available @ https://www.omrglobal.com/industry-reports/oral-contrast-agent-market

Global Oral Contrast Agent Market Report by Segment

By Type

  • Barium-based Contrast Media
  • Iodinated Contrast Media
  • Gadolinium-based Contrast Media
  • Microbubble Contrast Media

By Application 

  • CVD
  • Cancer
  • Gastrointestinal Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Nephrological Disorders

Global Oral Contrast Agent Market Report by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe

Asia-Pacific

  • India
  • China
  • Japan
  • South Korea
  • Rest of APAC

Rest of the World

  • Latin America
  • Middle East & Africa

Reasons to buy from us –

  1. We cover more than 15 major industries, further segmented into more than 90 sectors.
  2. More than 120 countries are for analysis.
  3. Over 100+ paid data sources mined for investigation.
  4. Our expert research analysts answer all your questions before and after purchasing your report.

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404